ERBB2 and cancer: This stark contrast in the HER2+/ER− SKBR-3 mirrors the clinical observation (Figure 10H,F) that high CLDN8 expression is linked to poor chemo-response in HER2-driven cancer; when CLDN8 is removed, the cells succumb much more readily to the taxane.